

Reference number(s)
1725-H

SPECIALTY QUANTITY LIMIT PROGRAM

AUSTEDO (deutetrabenazine)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Austedo 6 mg tablet	60 per 30 days	Chorea associated with Huntington's disease: 6 mg orally once daily
Austedo 9 mg tablet	120 per 30 days	Tardive dyskinesia in adults: 12 mg orally per day (one 6 mg tablet twice daily)
Austedo 12 mg tablet	120 per 30 days	For both above indications: May increase at weekly intervals in increments of 6 mg per day to a maximum daily dosage of 48 mg Switching from tetrabenazine dosing regimen: 6 mg orally once daily to 24 mg orally twice daily depending on current tetrabenazine daily dosage

III. REFERENCES

1. Austedo [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc. July 2019.